AR034244A1 - Derivados de 4-aminopiperidina y su uso como medicamento - Google Patents
Derivados de 4-aminopiperidina y su uso como medicamentoInfo
- Publication number
- AR034244A1 AR034244A1 ARP000106648A ARP000106648A AR034244A1 AR 034244 A1 AR034244 A1 AR 034244A1 AR P000106648 A ARP000106648 A AR P000106648A AR P000106648 A ARP000106648 A AR P000106648A AR 034244 A1 AR034244 A1 AR 034244A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- optionally substituted
- alkyl
- formula
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de 4-aminopiperidina de formula (1) en forma racémica, enantiomérica o en todas las combinaciones de estas formas, en la que: R1 representa un radical lineal o ramificado (C1-16)alquilo, alquenilo, alquinilo, -(CH2)m-Y-Z11 ó -(CH2)m-Z12 en el cual Z11 representa un (C1-6) alquilo o arilo opcionalmente sustituido, Z12 representa ciano, ciclohexilo, bis-fenilo, (C3-7)cicloalquilo, (C3-7) heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido, ó Z12 representa un radical de fórmula (2), (3) o (4); ó R1 representa un radical de fórmula (5), (6), (7) u (8); R2 representa un radical de fórmula -C(Y)NHX1, -C(O)X2 ó SO2X3; R3 representa el átomo de hidrógeno, un alquilo, alquenilo, alquinilo opcionalmente sustituido, aralquilo opcionalmente sustituido, un radical heteroarilalquilo opcionalmente sustituido, o un radical de fórmula -C(Y)-NHX1, -(CH2)n-C(O)X2, SO2X3 ó de fórmula (9) ó (10); X1 representa un radical lineal o ramificado (C1-15)alquilo, alquenilo, alquinilo, -(CH2)m-Y-Z21 ó -(CH2)pZ22 en el cual Z21 representa un (C1-6)alquilo; y Z22 representa ciclohexenilo, indanilo, bis-fenilo, (C3-7)cicloalquilo, (C3-7)heterocicloalquilo, mono- ó di-alquilamino, -C(O)-O-alquilo, o arilo o heteroarilo opcionalmente sustituido, ó Z22 representa un radical de fórmula (2) ó (4); X2 representa un radical lineal o ramificado (C1-10)alquilo, un radical alquenilo opcionalmente sustituido por un radical fenilo (el propio radical fenilo está opcionalmente sustituido), un radical alquinilo, o un radical de fórmula -(CH2)m-W-(CH2)q-Z23 ó -CH2)p-U-Z24 en el cual Z23 representa un (C1-6)alquilo o arilo opcionalmente sustituido; Z24 representa alquilo, ciclohexenilo, bis-fenilo, (C3-7)cicloalquilo opcionalmente sustituido, (C3-7)heterocicloalquilo, ciano, amino, mono ó dialquilamino, o arilo o heteroarilo opcionalmente sustituido, ó Z24 representa un radical de fórmula (11) a (15), donde r es 1, 2 ó 3; ó X2 representa un radical representado por las fórmulas (16) a (30), donde el grupo protector (PG) representa H o tert-butiloxicarbonilo; X3 representa un radical lineal o ramificado (C1-10)alquilo, un radical alquenilo opcionalmente sustituido por un radical fenilo (el propio radical fenilo está opcionalmente sustituido), CF3, ó -(CH2)pZ25 en el cual Z25 representa arilo o heteroalrilo opcionalmente sustituido, ó X3 representa un radical de fórmula (31) opcionalmente sustituido por uno o más radicales halo idénticos o distintos; Y representa un átomo de oxígeno o azufre; W representa un átomo de oxígeno o azufre, ó SO2; U representa un enlace covalente o el átomo de oxígeno; n es un número entero de 0 a 4; m es un número entero de 1 a 6; p es un número entero de 0 a 6; q es un número entero de 0 a 2, o sus sales de adición con ácidos orgánicos o minerales farmacéuticamente aceptables, excluyendo los compuestos de la fórmula general (1) en la cual R1 representa el radical alquilo, alquenilo o bencilo, R2 un benciloxi opcionalmente sustituido y R3 aralquilo. Procedimiento de preparación por métodos de síntesis en paralelo en fase líquida y sólida, medicamentos y composiciones farmacéuticas que contienen a dichos derivados, y uso de tales derivados para preparar medicamentos. Estos derivados tienen una buena afinidad con ciertos sub-tipos de receptores de la somatostatina y son especialmente útiles para tratar estados patológicos o enfermedades en las que están involucrados uno (o más) receptores de la somatostatina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9915724A FR2802206B1 (fr) | 1999-12-14 | 1999-12-14 | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034244A1 true AR034244A1 (es) | 2004-02-18 |
Family
ID=9553215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106648A AR034244A1 (es) | 1999-12-14 | 2000-12-14 | Derivados de 4-aminopiperidina y su uso como medicamento |
Country Status (23)
Country | Link |
---|---|
US (4) | US7115634B2 (es) |
EP (1) | EP1286966B1 (es) |
JP (2) | JP4838474B2 (es) |
KR (2) | KR100725190B1 (es) |
CN (1) | CN1207283C (es) |
AR (1) | AR034244A1 (es) |
AT (1) | ATE401308T1 (es) |
AU (1) | AU779341B2 (es) |
CA (1) | CA2394086C (es) |
CY (1) | CY1108415T1 (es) |
CZ (1) | CZ305360B6 (es) |
DE (1) | DE60039539D1 (es) |
DK (1) | DK1286966T3 (es) |
ES (1) | ES2310529T3 (es) |
FR (1) | FR2802206B1 (es) |
HK (1) | HK1054029A1 (es) |
HU (1) | HU227838B1 (es) |
MY (1) | MY126973A (es) |
NZ (1) | NZ520071A (es) |
PL (1) | PL204864B1 (es) |
PT (1) | PT1286966E (es) |
RU (1) | RU2266282C2 (es) |
WO (1) | WO2001044191A1 (es) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
JP4664564B2 (ja) * | 2000-03-06 | 2011-04-06 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン関連疾患の治療に使用する含窒素環式化合物 |
US20030171413A1 (en) * | 2000-08-17 | 2003-09-11 | Owen David Alan | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders |
US7208497B2 (en) | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
EP1411944A1 (en) * | 2001-08-03 | 2004-04-28 | Schering Corporation | Sulfonamide derivatives as gamma secretase inhibitors |
US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
DE60234616D1 (de) * | 2001-09-14 | 2010-01-14 | High Point Pharmaceuticals Llc | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren |
WO2003024928A2 (en) | 2001-09-14 | 2003-03-27 | Novo Nordisk A/S | Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
AU2002361345B8 (en) * | 2001-11-28 | 2008-06-26 | Ipsen Pharma S.A.S. | 5-sulphanyl-4H-1,2,4-triazole derivatives and their use as medicine |
FR2832710B1 (fr) * | 2001-11-28 | 2004-09-03 | Sod Conseils Rech Applic | Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments |
EP1461339B1 (en) | 2001-12-28 | 2010-04-28 | Acadia Pharmaceuticals Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
CA2473468C (en) * | 2002-02-01 | 2011-06-21 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
US7101898B2 (en) | 2002-02-01 | 2006-09-05 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
AU2003220222A1 (en) | 2002-03-13 | 2003-09-29 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
NZ537522A (en) * | 2002-06-24 | 2006-07-28 | Acadia Pharm Inc | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
WO2004009549A2 (en) * | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
SG170617A1 (en) | 2003-01-16 | 2011-05-30 | Acadia Pharm Inc | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
CA2530159C (en) * | 2003-06-17 | 2010-02-02 | Pfizer Inc. | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
GB0314054D0 (en) * | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
WO2006004880A2 (en) * | 2004-06-30 | 2006-01-12 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2006037043A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
US8221804B2 (en) | 2005-02-03 | 2012-07-17 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
PL1893603T3 (pl) | 2005-06-02 | 2010-03-31 | Hoffmann La Roche | Pochodne piperydyn-4-yloamidowe i ich zastosowanie jako antagonistów podtypu 5 receptora SST |
ES2375929T3 (es) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | Antagonistas del receptor histamina h3. |
US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
TW200812963A (en) * | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
SG163547A1 (en) * | 2006-05-29 | 2010-08-30 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
US7674804B2 (en) | 2006-06-29 | 2010-03-09 | Hoffmann-La Roche Inc. | Pyrimidine and quinazoline derivatives as SST5 modulators |
JP2010522198A (ja) | 2007-03-19 | 2010-07-01 | アカドイア プハルマセウチカルス インコーポレーテッド | 5−ht2aインバースアゴニスト及びアンタゴニストの抗精神病薬との併用 |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
EP2014656A3 (en) * | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
DK2200610T3 (en) * | 2007-09-21 | 2018-04-23 | Acadia Pharm Inc | ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS |
WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
EP2060564A1 (en) * | 2007-11-19 | 2009-05-20 | Ludwig-Maximilians-Universität München | Non-peptidic promoters of apoptosis |
WO2009132051A1 (en) | 2008-04-21 | 2009-10-29 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
ES2352398B1 (es) | 2009-06-25 | 2011-09-29 | Institut Univ. De Ciencia I Tecnologia S.A. | N-fenetilsulfonamidas-n-sustituidas para la identificacion de actividad biologica y farmacologica. |
EP3858847A1 (en) | 2011-11-30 | 2021-08-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
ES2727481T3 (es) * | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
EP2871179A4 (en) | 2012-07-03 | 2016-03-16 | Ono Pharmaceutical Co | CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
MX2015014666A (es) * | 2013-04-17 | 2016-03-01 | Pfizer | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. |
SG11201602477YA (en) | 2013-09-30 | 2016-05-30 | Ono Pharmaceutical Co | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
KR101541647B1 (ko) | 2014-04-24 | 2015-08-03 | 고려대학교 산학협력단 | 염증성 질환의 예방 또는 치료용 약학 조성물 |
US10597363B2 (en) | 2015-07-20 | 2020-03-24 | Acadia Pharmaceuticals Inc. | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C |
EP3341480A1 (en) | 2015-08-28 | 2018-07-04 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
US10525048B2 (en) | 2015-09-18 | 2020-01-07 | Memorial Sloan Kettering Cancer Center | Methods and compositions of inhibiting DCN1-UBC12 interaction |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
SG11201900349VA (en) | 2016-07-14 | 2019-02-27 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
BR112019019168A2 (pt) * | 2017-03-16 | 2020-04-14 | Crinetics Pharmaceuticals Inc | moduladores de somatostatina e usos dos mesmos |
WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
WO2019040104A2 (en) | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES |
BR112020003477A2 (pt) | 2017-08-21 | 2020-08-25 | Acadia Pharmaceuticals, Inc. | compostos e método para tratar uma doença |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
WO2019143718A1 (en) | 2018-01-17 | 2019-07-25 | Crinetics Pharmaceuticals, Inc. | Process of making somatostatin modulators |
MA51840A (fr) | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
WO2020061046A1 (en) | 2018-09-18 | 2020-03-26 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
WO2021030262A1 (en) | 2019-08-14 | 2021-02-18 | Crinetics Pharmaceuticals, Inc. | Nonpeptide somatostatin type 5 receptor agonists and uses thereof |
CN114867719A (zh) | 2019-11-06 | 2022-08-05 | 柳韩洋行 | 吡咯烷和哌啶化合物 |
CN116730981A (zh) * | 2020-07-22 | 2023-09-12 | 山东绿叶制药有限公司 | 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用 |
MX2023002761A (es) | 2020-09-09 | 2023-04-03 | Crinetics Pharmaceuticals Inc | Formulaciones de un modulador de somatostatina. |
CA3207378A1 (en) | 2021-02-17 | 2022-08-25 | Yuxin Zhao | Crystalline forms of a somatostatin modulator |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1425354A (en) | 1973-10-10 | 1976-02-18 | Wyeth John & Brother Ltd | Indole derivatives |
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
JPS5152176A (es) * | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
JPS5285174A (en) * | 1976-01-05 | 1977-07-15 | Yoshitomi Pharmaceut Ind Ltd | Novel urea or thiourea derivatives |
GB1574418A (en) * | 1976-11-16 | 1980-09-03 | Anphar Sa | Piperidine derivatives |
US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
WO1999022735A1 (en) * | 1997-10-30 | 1999-05-14 | Merck & Co., Inc. | Somatostatin agonists |
AU2654399A (en) * | 1998-02-02 | 1999-08-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
ES2250128T3 (es) * | 1999-05-17 | 2006-04-16 | Novo Nordisk A/S | Antagonistas/agonistas inversos de glucagon. |
US6344358B1 (en) | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
JP4664564B2 (ja) * | 2000-03-06 | 2011-04-06 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン関連疾患の治療に使用する含窒素環式化合物 |
-
1999
- 1999-12-14 FR FR9915724A patent/FR2802206B1/fr not_active Expired - Lifetime
-
2000
- 2000-12-13 EP EP00993405A patent/EP1286966B1/fr not_active Expired - Lifetime
- 2000-12-13 WO PCT/FR2000/003497 patent/WO2001044191A1/fr active IP Right Grant
- 2000-12-13 ES ES00993405T patent/ES2310529T3/es not_active Expired - Lifetime
- 2000-12-13 MY MYPI20005862A patent/MY126973A/en unknown
- 2000-12-13 DK DK00993405T patent/DK1286966T3/da active
- 2000-12-13 US US10/130,924 patent/US7115634B2/en not_active Expired - Lifetime
- 2000-12-13 CN CNB008171777A patent/CN1207283C/zh not_active Expired - Lifetime
- 2000-12-13 AU AU28560/01A patent/AU779341B2/en not_active Expired
- 2000-12-13 NZ NZ520071A patent/NZ520071A/xx not_active IP Right Cessation
- 2000-12-13 RU RU2002118705/04A patent/RU2266282C2/ru active
- 2000-12-13 PT PT00993405T patent/PT1286966E/pt unknown
- 2000-12-13 KR KR1020027007506A patent/KR100725190B1/ko active IP Right Grant
- 2000-12-13 PL PL356365A patent/PL204864B1/pl unknown
- 2000-12-13 CZ CZ2002-2060A patent/CZ305360B6/cs not_active IP Right Cessation
- 2000-12-13 DE DE60039539T patent/DE60039539D1/de not_active Expired - Lifetime
- 2000-12-13 CA CA2394086A patent/CA2394086C/fr not_active Expired - Lifetime
- 2000-12-13 JP JP2001544681A patent/JP4838474B2/ja not_active Expired - Lifetime
- 2000-12-13 AT AT00993405T patent/ATE401308T1/de active
- 2000-12-13 HU HU0204515A patent/HU227838B1/hu unknown
- 2000-12-13 KR KR1020077001118A patent/KR20070014235A/ko not_active Application Discontinuation
- 2000-12-14 AR ARP000106648A patent/AR034244A1/es active IP Right Grant
-
2003
- 2003-09-03 HK HK03106281.2A patent/HK1054029A1/xx not_active IP Right Cessation
-
2005
- 2005-05-04 US US11/122,293 patent/US7393861B2/en not_active Expired - Lifetime
-
2008
- 2008-05-02 US US12/151,115 patent/US7858789B2/en not_active Expired - Fee Related
- 2008-10-14 CY CY20081101138T patent/CY1108415T1/el unknown
-
2010
- 2010-11-15 US US12/946,504 patent/US8110574B2/en not_active Expired - Fee Related
-
2011
- 2011-02-07 JP JP2011024405A patent/JP2011121982A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034244A1 (es) | Derivados de 4-aminopiperidina y su uso como medicamento | |
MY138452A (en) | Novel process for synthesizing and a novel crystal form of agomelatine as well as pharmaceutical preparations containing these | |
AR034173A1 (es) | Un compuesto de piperazina sustituida, composiciones farmaceuticas y el uso de los mismos para la elaboracion de medicamentos | |
EA200800285A1 (ru) | Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk | |
AR033306A1 (es) | Compuestos | |
JO2935B1 (en) | 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine) | |
FR2662162B1 (fr) | Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. | |
TW200635585A (en) | Monocyclic substituted methanones | |
AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
AR057383A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
AR007077A1 (es) | Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento | |
DE60330407D1 (de) | Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung | |
NZ307505A (en) | Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | |
PE20040666A1 (es) | Derivados novedosos de piperidina | |
NO20060383L (no) | Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister | |
SE9703377D0 (sv) | New compounds | |
AR006360A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion. | |
NZ333513A (en) | 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists | |
AR049023A1 (es) | Imidazoles como inihibidores de la hmg-coa reductasa | |
PE20001495A1 (es) | Derivados de mevinolina | |
DE602004029355D1 (de) | Sulfopyrrolderivate | |
TNSN07395A1 (en) | Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives | |
PE20020426A1 (es) | ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN | |
AR043273A1 (es) | Derivados de bifenilo, su uso, un proceso para prepararlos y medicamentos que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |